drugset / Trial / NCT01825447
A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users
Phase 1
Completed
89 enrolled
Pfizer
Lifetree Clinical Research Center, Salt Lake City, Utah · collab
RandomizedCrossoverDouble-blindBasic science
Summary
The main purpose of this study is to simulate if oxycodone and naltrexone combination capsules (ALO-02) were to be tampered with by dissolving and then injecting intravenously for the purpose of getting high.
Timeline
- Start
- 2013-07
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | 2.4 mg | Intravenous |
| Comparator | Oxycodone | Other / unclassified | 20 mg | Intravenous |
Indications
No indication recorded.